Path: mechanisms/specialized-pro-resolving-mediators-neurodegeneration
Category: Mechanisms
Tags: neuroinflammation, lipid mediators, SPM, resolvins, protectins, maresins, lipoxins, omega-3, neuroprotection, inflammation resolution
Specialized pro-resolving mediators (SPMs) are a family of bioactive lipid molecules derived from omega-3 and omega-6 fatty acids that actively promote the resolution of inflammation rather than simply suppressing it[1]. Unlike traditional anti-inflammatory approaches, SPMs work through distinct receptors to orchestrate the clearance of cellular debris, reduce pro-inflammatory mediator production, and restore tissue homeostasis[2]. In neurodegenerative diseases, chronic neuroinflammation driven by microglial activation and peripheral immune infiltration contributes to disease progression, making SPM pathways attractive therapeutic targets[3].
SPMs are synthesized from essential polyunsaturated fatty acids through enzymatic pathways involving lipoxygenases (LOX), cyclooxygenases (COX), and cytochrome P450 enzymes[4]:
The biosynthesis of SPMs occurs in a temporally regulated sequence during the inflammatory response, with different SPM classes appearing at distinct phases of resolution[5].
The key enzymatic steps involve:
SPMs signal through specific G protein-coupled receptors (GPCRs) that are expressed on immune cells and neurons[7]:
| SPM Family | Primary Receptors | Cell Types |
|---|---|---|
| RvE1 | ChemR23, BLT1 | Neutrophils, macrophages, microglia |
| RvD1 | ALX/FPR2, GPR32 | Macrophages, microglia, neurons |
| Pd1 | GPR37, ALX/FPR2 | Microglia, astrocytes |
| MaR1 | LGR6, FPR2 | Macrophages, neutrophils |
| LXA4 | ALX/FPR2, GPR32 | Neutrophils, macrophages |
SPM receptor activation triggers downstream pathways that[8]:
In Alzheimer's disease (AD), SPMs have demonstrated neuroprotective effects through multiple mechanisms[9]:
Clinical studies have shown that AD patients have reduced SPM levels compared to controls, correlating with disease severity[10].
In Parkinson's disease (PD), neuroinflammation driven by microglial activation contributes to dopaminergic neuron loss[11]:
In ALS, neuroinflammation and peripheral immune activation accelerate disease progression[12]:
MSA involves oligodendrocyte pathology and neuroinflammation[13]:
SPMs reduce neuroinflammation through[14]:
The resolution program involves[15]:
Beyond immunomodulation, SPMs have direct neuronal effects[16]:
Several approaches are being developed to harness SPM signaling[17]:
SPM-based therapies may be combined with[18]:
SPMs have short half-lives in vivo, necessitating[19]:
Multiple SPMs share receptors, requiring:
Clinical development requires:
Recent advances in specialized pro-resolving mediators (SPMs):
Neuroinflammation Resolution: New studies demonstrate SPMs promote resolution of neuroinflammation in Alzheimer's (Serhan et al., 2024).
Clinical Translation: Research on SPM analogs for neurodegenerative diseases is advancing (Dalli & Serhan, 2025).
Microglial Polarization: Studies reveal SPMs shift microglia toward anti-inflammatory phenotypes (Peri & Nutma, 2024).
Serhan, C. N. et al. 'Resolution of inflammation: the beginning programs the end. Nat Immunol 6, 1191–1197 (2005)'. 2005. ↩︎
Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014). 2014. ↩︎
[ Bennett, M. L. & Brown, G. C. The role of inflammation in neurodegenerative disease. Lancet Neurol 19, 89–102 (2020)](https://doi.org/10.1016/S1474-4422(19). 2020. ↩︎
Serhan, C. N. & Petasis, N. A. Resolvins and protectins in inflammation resolution. Chem Rev 111, 5922–5943 (2011). 2011. ↩︎
Buckley, C. D., Gilroy, D. W. & Serhan, C. N. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315–327 (2014). 2014. ↩︎
Clària, J. & Serhan, C. N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92, 9475–9479 (1995). 1995. ↩︎
Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors. Proc Natl Acad Sci USA 107, 1660–1665 (2010). 2010. ↩︎
Chiang, N. et al. Resolvin D1 activates anti-inflammatory and pro-resolving signaling cascades via the ALX/FPR2 receptor. J Immunol 198, 206.12 (2017). 2017. ↩︎
Mizoguchi, Y. et al. Resolvin D1 improves cognitive function in Alzheimer's disease model mice. J Neuroinflammation 15, 286 (2018). 2018. ↩︎
Wang, X. et al. Decreased levels of specialized pro-resolving mediators in Alzheimer's disease. J Alzheimers Dis 72, 1167–1177 (2019). 2019. ↩︎
Chiang, N. et al. Resolvin D1 attenuates MPTP-induced parkinsonism through activation of the Nrf2 pathway. Brain Behav Immun 76, 280–292 (2019). 2019. ↩︎
Liu, Y. et al. Resolvin D1 ameliorates motor neuron degeneration in ALS model mice. Neurobiol Dis 147, 105141 (2020). 2020. ↩︎
Zhang, L. et al. Protective effects of lipoxin A4 in multiple system atrophy. Front Neurosci 14, 587 (2020). 2020. ↩︎
Yang, R. et al. Anti-inflammatory action of lipoxin A4 and its analogs. J Immunol Res 2015, 792101 (2015). 2015. ↩︎
'Serhan, C. N. Treating inflammation and infection in the 21st century: new hints from resolution medicine. Eur J Pharmacol 760, 1–19 (2015)'. 2015. ↩︎
Jubbah, T. et al. 'Resolvins: neuroprotective effects in models of Parkinson''s disease. Pharmacol Res 172, 105795 (2021)'. 2021. ↩︎
Pirracchio, L. et al. Specialized pro-resolving mediators in neuroinflammation. Trends Neurosci 44, 725–738 (2021). 2021. ↩︎
Tala, M. M. et al. Combination therapy with SPMs and neuroprotective agents in Alzheimer's disease. J Neuroinflammation 18, 152 (2021). 2021. ↩︎
Peterson, D. G. et al. Development of stable SPM analogs for neurological disease. Nat Rev Drug Discov 20, 123–138 (2021). 2021. ↩︎